253 related articles for article (PubMed ID: 25461330)
21. Novel heteroaromatic organofluorine inhibitors of fructose-1,6-bisphosphatase.
Rudnitskaya A; Huynh K; Török B; Stieglitz K
J Med Chem; 2009 Feb; 52(3):878-82. PubMed ID: 19143528
[TBL] [Abstract][Full Text] [Related]
22. Fructose-1,6-bisphosphatase Inhibitors: A Review of Recent (2000- 2017) Advances and Structure-Activity Relationship Studies.
Singh S; Harmalkar DS; Choi Y; Lee K
Curr Med Chem; 2019; 26(29):5542-5563. PubMed ID: 30182843
[TBL] [Abstract][Full Text] [Related]
23. Discovery of di-indolinone as a novel scaffold for protein tyrosine phosphatase 1B inhibitors.
Dai HL; Gao LX; Yang Y; Li JY; Cheng JG; Li J; Wen R; Peng YQ; Zheng JB
Bioorg Med Chem Lett; 2012 Dec; 22(24):7440-3. PubMed ID: 23122522
[TBL] [Abstract][Full Text] [Related]
24. Protein-based alignment in 3D-QSAR of FBPase inhibitors.
Yi P; Di YT; Liu W; Hao XJ; Ming Y; Huang DS; Yang J; Yi ZZ; Li ZJ; Yang RD; Zhang JC
Eur J Med Chem; 2011 Mar; 46(3):885-92. PubMed ID: 21269737
[TBL] [Abstract][Full Text] [Related]
25. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Dang Q; Brown BS; Liu Y; Rydzewski RM; Robinson ED; van Poelje PD; Reddy MR; Erion MD
J Med Chem; 2009 May; 52(9):2880-98. PubMed ID: 19348494
[TBL] [Abstract][Full Text] [Related]
26. Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus.
Kaur R; Dahiya L; Kumar M
Eur J Med Chem; 2017 Dec; 141():473-505. PubMed ID: 29055870
[TBL] [Abstract][Full Text] [Related]
27. Designing inhibitors against fructose 1,6-bisphosphatase: exploring natural products for novel inhibitor scaffolds.
Heng S; Harris KM; Kantrowitz ER
Eur J Med Chem; 2010 Apr; 45(4):1478-84. PubMed ID: 20116906
[TBL] [Abstract][Full Text] [Related]
28. Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.
Xu YX; Huang YY; Song RR; Ren YL; Chen X; Zhang C; Mao F; Li XK; Zhu J; Ni SS; Wan J; Li J
Eur J Med Chem; 2020 Oct; 203():112500. PubMed ID: 32711108
[TBL] [Abstract][Full Text] [Related]
29. 1,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase inhibitors.
Renton P; Speed J; Maddaford S; Annedi SC; Ramnauth J; Rakhit S; Andrews J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5301-4. PubMed ID: 21813276
[TBL] [Abstract][Full Text] [Related]
30. A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase.
Heng S; Gryncel KR; Kantrowitz ER
Bioorg Med Chem; 2009 Jun; 17(11):3916-22. PubMed ID: 19419876
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel oxindole derivatives as potent α-glucosidase inhibitors.
Khan M; Yousaf M; Wadood A; Junaid M; Ashraf M; Alam U; Ali M; Arshad M; Hussain Z; Khan KM
Bioorg Med Chem; 2014 Jul; 22(13):3441-8. PubMed ID: 24825482
[TBL] [Abstract][Full Text] [Related]
32. New insight into the binding modes of TNP-AMP to human liver fructose-1,6-bisphosphatase.
Han X; Huang Y; Zhang R; Xiao S; Zhu S; Qin N; Hong Z; Wei L; Feng J; Ren Y; Feng L; Wan J
Spectrochim Acta A Mol Biomol Spectrosc; 2016 Aug; 165():155-160. PubMed ID: 27137358
[TBL] [Abstract][Full Text] [Related]
33. Interaction between muscle aldolase and muscle fructose 1,6-bisphosphatase results in the substrate channeling.
Rakus D; Pasek M; Krotkiewski H; Dzugaj A
Biochemistry; 2004 Nov; 43(47):14948-57. PubMed ID: 15554702
[TBL] [Abstract][Full Text] [Related]
34. Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites.
Hebeisen P; Kuhn B; Kohler P; Gubler M; Huber W; Kitas E; Schott B; Benz J; Joseph C; Ruf A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4708-12. PubMed ID: 18650089
[TBL] [Abstract][Full Text] [Related]
35. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Erion MD; van Poelje PD; Dang Q; Kasibhatla SR; Potter SC; Reddy MR; Reddy KR; Jiang T; Lipscomb WN
Proc Natl Acad Sci U S A; 2005 May; 102(22):7970-5. PubMed ID: 15911772
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel mono and bis-indole conduritol derivatives and their α/β-glycosidase inhibitory effects.
Çavdar H; Talaz O; Ekinci D
Bioorg Med Chem Lett; 2012 Dec; 22(24):7499-503. PubMed ID: 23137433
[TBL] [Abstract][Full Text] [Related]
37. Determination of protein-ligand binding constants of a cooperatively regulated tetrameric enzyme using electrospray mass spectrometry.
Cubrilovic D; Haap W; Barylyuk K; Ruf A; Badertscher M; Gubler M; Tetaz T; Joseph C; Benz J; Zenobi R
ACS Chem Biol; 2014 Jan; 9(1):218-26. PubMed ID: 24128068
[TBL] [Abstract][Full Text] [Related]
38. The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase.
Jackson RW; LaPorte MG; Herbertz T; Draper TL; Gaboury JA; Rippin SR; Patel R; Chunduru SK; Benetatos CA; Young DC; Burns CJ; Condon SM
Bioorg Med Chem Lett; 2011 Jun; 21(11):3227-31. PubMed ID: 21550237
[TBL] [Abstract][Full Text] [Related]
39. Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2010 Feb; 20(3):1004-7. PubMed ID: 20045638
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of substituted 2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamine related compounds as fructose-1,6-bisphosphatase inhibitors.
Rosini M; Mancini F; Tarozzi A; Colizzi F; Andrisano V; Bolognesi ML; Hrelia P; Melchiorre C
Bioorg Med Chem; 2006 Dec; 14(23):7846-53. PubMed ID: 16908175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
